A. Parton

发表

Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis

Lei Wu, G. Baillie, M. Houslay, 2010, British Journal of Pharmacology.

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

J. Kosek, S. Surapaneni, P. Schafer, 2012, Cancer Chemotherapy and Pharmacology.

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.

P. Schafer, D. Stirling, A. Gandhi, 2006, Leukemia research.

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

Lei Wu, P. Schafer, Ling Lu, 2010, Cancer Immunology, Immunotherapy.

CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production

M. Palmisano, G. Horan, F. Ramírez-Valle, 2022, Arthritis Research & Therapy.

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

L. Sapinoso, G. Hampton, T. Tran, 2010, Current cancer drug targets.

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Jilly F. Evans, R. Chopra, P. Schafer, 2014, Cellular signalling.

Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.

C. Hughes, Lei Wu, P. Schafer, 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

R. Chopra, Lei Wu, J. Kosek, 2012 .

Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.

Lei Wu, Lei Wu, J. Kosek, 2016, Cellular signalling.

Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity.

P. Schafer, Alexander L. Ruchelman, L. Corral, 2013, Bioorganic & medicinal chemistry letters.

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

T. Tran, L. Sapinoso, G. Hampton, 2010 .

Safety, Pharmacokinetics, and Antifibrotic Activity of CC‐90001 (BMS‐986360), a c‐Jun N‐Terminal Kinase Inhibitor, in Pulmonary Fibrosis

M. Palmisano, G. Horan, F. Ramírez-Valle, 2023, Clinical pharmacology in drug development.

Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis

Lei Wu, G. Baillie, P. Schafer, 2010, British journal of pharmacology.

Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.

Lei Wu, J. Kosek, A. Marconi, 2016, Cellular signalling.

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Jilly F. Evans, R. Chopra, P. Schafer, 2014, Cellular signalling.